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Abstract: Talimogene laherparepvec is a herpes simplex virus-1-based intralesional oncolytic 
immunotherapy and is the first oncolytic virus to be approved in Europe. It is indicated for 
the treatment of adults with unresectable melanoma that is regionally or distantly metastatic 
(stage IIIB, IIIC, and IVM1a) with no bone, brain, lung, or other visceral disease. Talimogene 
laherparepvec is a genetically modified viral therapy, and its handling needs special attention due 
to its deep freeze, cold-chain requirements, its potential for viral shedding, and its administration 
by direct intralesional injection. This review provides a practical overview of handling, storage, 
and administration procedures for this agent in Europe. Talimogene laherparepvec vials should be 
transported/stored frozen at a temperature of ‑90°C to ‑70°C, and once thawed, vials must not be 
refrozen. Universal precautions for preparation, administration, and handling should be followed 
to avoid accidental exposure. Health care providers should wear personal protective equipment, 
and materials that come into contact with talimogene laherparepvec should be disposed of in 
accordance with local institutional procedures. Individuals who are immunocompromised or 
pregnant should not prepare or administer this agent. Talimogene laherparepvec is administered 
by intralesional injection into cutaneous, subcutaneous, and/or nodal lesions that are visible, 
palpable, or detectable by ultrasound. Treatment should be continued for $6 months. As with 
other immunotherapies, patients may experience an increase in the size of existing lesion(s) or the 
appearance of new lesions (ie, progression) prior to achieving a response (“pseudo-progression”). 
As several health care professionals (eg, physicians [dermatologists, surgeons, oncologists, 
radiologists], pharmacists, nurses) are involved in different stages of the process, there is a 
need for good interdisciplinary collaboration when using talimogene laherparepvec. Although 
there are specific requirements for this agent’s storage, handling, administration, and disposal, 
these can be effectively managed in a real-world clinical setting through the implementation 
of training programs and straightforward standard operating procedures.
Keywords: herpes simplex virus, intralesional injection, melanoma, oncolytic immunotherapy, 
practical considerations, talimogene laherparepvec
Introduction
Due to the high incidence of skin (cutaneous/subcutaneous) and lymph node 
metastases in melanoma, direct intralesional injection is clinically feasible in many 
patients1,2 and could, for example, be an option in patients with in-transit disease. 
The aim of intralesional oncolytic immunotherapy is to regress the injected lesion 
while also producing immunologic effects at distant sites in uninjected lesions.3 This 
can be achieved when the injected agent induces regional and systemic immune 
responses to melanoma antigens. Various intralesional therapies have been tested in 
melanoma, including Bacillus Calmette–Guérin inoculation,4 rose Bengal,5 cytokine-
based therapies (eg, interleukin [IL]-2,6 interferon,7 granulocyte–macrophage 
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colony-stimulating factor [GM-CSF],8 and naked plasmid 
DNA encoding IL-129), and virus-based therapies like the 
herpes simplex virus type-1 (HSV-1)-based agents HSV 
171610 and HF1011 and Coxsackievirus A21.12 Furthermore, 
adenovirus13- and measles virus14-based therapeutics have been 
evaluated as potential treatments for cutaneous lymphomas.
Talimogene laherparepvec – a new 
intralesional oncolytic immunotherapy for 
melanoma
Oncolytic viruses aim to selectively infect, replicate within, and 
lyse tumor cells, without harming normal tissues.15–17 Talimo-
gene laherparepvec (IMLYGIC®, Amgen Europe B.V., Breda, 
the Netherlands) is the first intralesional oncolytic immuno-
therapy based on HSV-118 with proven efficacy in a Phase III 
clinical trial,19 although other HSV-1-based melanoma therapies 
(eg, HF1011 and HSV 171610) are in development. Talimogene 
laherparepvec is the first treatment of its type to be approved 
in Europe20 and the US.21 It is indicated in Europe for the treat-
ment of adults with unresectable melanoma that is regionally 
or distantly metastatic (stage IIIB, IIIC, and IVM1a) with no 
bone, brain, lung, or other visceral disease.22 In the UK, the 
National Institute for Health and Care Excellence has recently 
approved the reimbursement of talimogene laherparepvec in 
patients with the same disease stage for whom systemically 
administered immunotherapy is not suitable (treatment must 
be provided in the context of a patient access scheme).20 
Various genetic modifications (ie, deletion of the infected 
cell protein [ICP]34.5 and ICP47 genes and insertion of the 
human GM-CSF gene) support the selective replication of 
talimogene laherparepvec in tumor cells and its antitumor 
activity (Table 1).23 The proposed mechanism of action com-
prises both local and systemic effects (Figure 1).15,17,18,23–26 
Selective replication of talimogene laherparepvec within 
infected tumor cells results in oncolysis and the release of 
progeny viruses, which can then infect additional tumor 
cells in the surrounding area, repeating the cycle.17,24,25 The 
oncolytic release of viral and tumor-specific antigens prompts 
dendritic cell recruitment, while release of the cytokine GM-
CSF leads to dendritic cell maturation. Dendritic cells then 
process and present tumor antigens to T cells in the lymph 
nodes,15,26 potentially inducing the activation and expansion 
of tumor-specific CD8+ T cells and the initiation of a tumor-
specific systemic immune response.15,23,26
Although the early phase trials of talimogene laher-
parepvec included patients with a variety of solid tumors,23,27 
clinical development to date has focused on melanoma. Mela-
noma was selected due to the availability of accessible lesions 
for direct injection and because an active role for the immune 
system has been implicated in this type of cancer. In the ran-
domized open-label Phase III Oncovex (GM-CSF) Pivotal 
Trial in Melanoma (OPTiM) trial (NTC00769704), talimo-
gene laherparepvec statistically significantly improved dura-
ble response rates (DRRs; continuous response of $6 months 
beginning within the first 12 months of therapy, and assessed 
using modified World Health Organization [WHO] criteria 
[primary end point]); overall response rates (ORRs) and 
complete response (CR) rates were also higher compared with 
GM-CSF in patients with unresectable stage IIIB–IVM1c 
melanoma (Table 2).19,28,29 Notably, responses to talimogene 
laherparepvec occurred in both injected and uninjected 
lesions in this study, supporting a potential systemic immune 
effect. Overall, 64% of injected lesions, 34% of uninjected 
non-visceral lesions, and 15% of uninjected visceral lesions 
decreased in size by $50%.30 Efficacy was most pronounced 
in patients with melanoma that was regionally or distantly 
metastatic, with no visceral disease (ie, stage IIIB, IIIC, or 
IVM1a;29 Table 2).28 As seen in the intent-to-treat popula-
tion, the DRR (25.2% vs 1.2%; P,0.0001 [descriptive]) and 
ORR (40.5% vs 2.3%; P,0.0001 [descriptive]) were higher 
with talimogene laherparepvec compared with GM-CSF in 
patients with stage IIIB, IIIC, and IVM1a melanoma.29
Due to its unique mechanism of action and favorable tox-
icity profile, talimogene laherparepvec also has the potential 
to be combined with other therapies; trials are ongoing.18 
Initial results for this agent in a Phase Ib/II combination with 
ipilimumab (NCT01740297)31,32 or a Phase Ib/III combina-
tion with pembrolizumab (NCT02263508)33 in patients with 
advanced melanoma are promising. Furthermore, a Phase II 
trial (NCT02211131) is ongoing assessing the efficacy of 
Table 1 Characteristics/modifications of talimogene laherpare­
pvec and their impact on safety and antitumor response
Characteristic/modification Rationale
Deletion of ICP34.5 (neurovirulence  
factor)
Mediates tumor­selective 
replication
Deletion of ICP47 Restores antigen presentation 
(enhances the antitumor 
immune response)
early/increased US11 expression increases replication of 
ICP34.5­deleted HSV
insertion of human GM-CSF gene enhances the antitumor 
immune response
Use of a new HSV­1 strain (JS1) improves tumor cell lysis
intact thymidine kinase gene Fully susceptible to acyclovir 
and ganciclovir
Note: Data from Liu et al.23
Abbreviations: GM­CSF, granulocyte–macrophage colony­stimulating factor; 
HSV­1, herpes simplex virus­1; ICP, infected cell protein.
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talimogene laherparepvec as a neoadjuvant treatment in 
patients with resectable melanoma. Additional trials are eval-
uating this agent in other tumor types. For instance, a Phase I 
trial (NCT02509507) is in progress assessing the safety and 
efficacy of talimogene laherparepvec in patients with injectable 
tumor lesions in the liver (hepatocellular carcinoma or liver 
metastases from a variety of solid tumors).18 A Phase Ib/III 
(NCT02626000) trial is also underway evaluating talimogene 
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Figure 1 Proposed mechanism of action of talimogene laherparepvec. Copyright of Amgen inc., reproduced with permission.
Abbreviations: GM­CSF, granulocyte–macrophage colony­stimulating factor; HSV­1, herpes simplex virus­1; MHC, major histocompatibility complex; TCR, T cell receptor; 
TDAs, tumor­derived antigens; T­VEC, talimogene laherparepvec.
Table 2 Summary of key efficacy data from OPTiM
ITT (stage IIIB–IVM1c) Stage IIIB–IVM1a subseta
T-VEC (n=295) GM-CSF (n=141) T-VEC (n=163) GM-CSF (n=86)
Durable response rate, n (%) 48 (16.3) 3 (2.1) 41 (25.2) 1 (1.2)
Treatment difference, % (95% Ci) 14.1 (9.3–19.0) 24.0 (17.0–31.0)
P­value ,0.0001 ,0.0001b
Best response, n (%)
Complete response 32 (10.8) 1 (0.7) 27 (16.6) 0 (0.0)
Partial response 46 (15.6) 7 (5.0) 39 (23.9) 2 (2.3)
Objective response rate, % (95% CI) 26.4 (21.4–31.5) 5.7 (1.9–9.5) 40.5 (32.9–48.4) 2.3 (0.3–8.1)
P­value ,0.0001b ,0.0001b
Overall survival, median – months (95% Ci) 23.3 (19.5–29.6) 18.9 (16.0–23.7) 41.1 (30.6–NR) 21.5 (17.4–29.6)
HR (95% Ci) 0.79 (0.62–1.00) 0.57 (0.40–0.80)
P­value 0.051 ,0.001b
Notes: aAnalyses are exploratory for this subpopulation. bDescriptive P­value. Data from Andtbacka et al19 and Harrington et al.28
Abbreviations: CI, confidence interval; GM­CSF, granulocyte–macrophage colony­stimulating factor; HR, hazard ratio; ITT, intent­to­treat; NR, not reached; OPTiM, 
Oncovex (GM­CSF) Pivotal Trial in Melanoma; T­VEC, talimogene laherparepvec.
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laherparepvec in combination with pembrolizumab in patients 
with recurrent or metastatic squamous cell carcinoma of the 
head and neck.
The aim of this review is to provide practical informa-
tion on the handling, storage, and administration proce-
dures for talimogene laherparepvec in Europe, in line with 
the European and other applicable summaries of product 
characteristics (SmPCs).22,34
Practical considerations for 
talimogene laherparepvec handling and 
administration
Talimogene laherparepvec is a recently approved, genetically 
modified, virus therapy, and its handling requires special 
attention due to its deep freeze, cold-chain requirements 
and its potential for viral shedding, as well as the direct 
intralesional administration. A summary of the various 
procedures that need to be considered in relation to talimo-
gene laherparepvec handling and administration is shown in 
Figure 2. Nonetheless, the regulatory environment with respect 
to genetically modified organisms (GMOs) has changed in 
recent years with regulations becoming less stringent since the 
initiation of the early Phase I/II studies of talimogene laher-
parepvec. For example, 10 years ago in the UK, there was a 
requirement for talimogene laherparepvec to be administered 
in negative-pressure, gene therapy side rooms, whereas now, 
it can be given routinely in an outpatient clinic/medical day 
unit setting (author personal experience).
Transportation and storage
Talimogene laherparepvec is provided in the form of single-
use 1-mL vials, which are color-coded depending on the 
•?????????????????????????????????????????????????????? ?????????????????????????????????????????? ???????????????????????????????????????????????????
•?? ???????????????????????????????????????????????????? ???????????????????????????????????????????????????? ????????????????
•??????????????????????????????????????????????????????????? ????????????????????????????
•?? ?????????????????? ??????????????????????????? ?????????????????????????????????????????????????????? ?????????????????????°???°??????????????????????????????
•??????????????????°????????°????????????????????????????? ????????????????????????????
•????????????????????°????????°??????????????????????????? ???????????????????????
•??????????????????????????
•??????????????? ??????????????? ???????????????????? ??????????????????°???°???????????????????????????????? ??????????
•?????????????????????????? ????????????????????????? ???????????????????????????????????????????????????
•????????????? ?????????????????????????????????????????? ?????????????????????????????????????????????????
•??????????????????????????
•??????????????????????????????????????????
•??????????????????????????????????????????
??????????????????????????????????????????
?????????????????????????????????
???????????????????????????????????????????
???????????????????????????????????
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Figure 2 Overview of the talimogene laherparepvec handling and administration process.
Abbreviations: PFU, plaque­forming units; Q2W, once every 2 weeks.
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concentration of virus contained within; vials with light 
green caps contain 106 plaque-forming units (PFU)/mL, 
whereas the vials with blue caps contain 108 PFU/mL.22 
The units used for quantifying this agent are different from 
many other anticancer therapies because it is an oncolytic 
virus and hence produces regions of cell destruction within a 
cell culture (viral “plaques”) when it replicates and spreads. 
PFU is a measure of the number of virus particles capable 
of forming plaques per unit volume (ie, mL). Talimogene 
laherparepvec is classified as an advanced therapy medici-
nal product (ATMP) by the European Medicines Agency 
(EMA), and so, a system that permits the complete trace-
ability of the patient and product is essential.35 To permit 
linkage of each talimogene laherparepvec batch to the patient 
who received it and vice versa, a record with sufficient 
details is required. 
At the time of writing, the recommendations for 
trans porting, storing, and preparing talimogene laher-
parepvec are summarized as follows; however, health care 
professionals (HCPs) are advised to regularly check the 
talimogene laherparepvec (IMLYGIC®) SmPC for current 
recommendations.22,34 The vials need to be transported, 
distributed, and stored frozen at a temperature of ‑90°C 
to ‑70°C, protected from light in their original cartons. The 
unopened vials have a shelf-life of up to 4 years. A hospital-
supplied spill kit should be transported alongside the vials 
or, alternatively, spill kits should be available throughout 
the hospital site. Talimogene laherparepvec is delivered 
on dry ice in a time-sensitive storage container, which will 
maintain the correct temperature for up to 96 hours from 
the time the container was sealed for shipment (the time 
the container will expire is printed on the exterior of the 
package). This container may include a temperature probe 
that monitors the temperature throughout the entire delivery 
process. If the temperature logger is “alarmed” (ie, shows a 
temperature excursion), the product should be quarantined 
until the manufacturer has confirmed whether the product is 
still usable. Talimogene laherparepvec can either be left in 
the container (for up to 96 hours) until it is used, or the prod-
uct can be removed and placed in a freezer at a temperature 
of ‑90°C to ‑70°C.22 While frozen, this agent must not be 
exposed to ambient temperature for longer than 60 seconds. 
Therefore, any transfer to a freezer must be performed within 
this timeframe. Talimogene laherparepvec can potentially 
be stored, prepared, and administered in various locations 
at different centers (eg, pharmacy, clinic, or on the ward), 
depending on local requirements. For example, depending 
on local standard operating procedures (SOPs), talimogene 
laherparepvec may be thawed and prepared in the pharmacy, 
transported to the clinic in preloaded syringes, and adminis-
tered in either inpatient or outpatient settings. Alternatively, 
it can be thawed and drawn up by clinicians at the bedside 
immediately before it is administered to the patient, as is 
routinely done at some sites in Switzerland (author personal 
experience).
Dosage and administration
Ahead of thawing, the target lesion(s) should be measured to 
determine the volume of talimogene laherparepvec needed 
(the injection volume is based on the size of the target lesion; 
Table 3).22 Once the required total volume (up to a maximum 
of 4 mL per treatment visit) has been determined, the required 
number of vials should be thawed in their original cartons at 
room temperature (20°C–25°C) until liquid (approximately 
30 minutes) swirling (but not shaking) to aid thawing as 
needed. Once thawed, talimogene laherparepvec can be 
Table 3 Talimogene laherparepvec dosing schedule, including injection volumes based on lesion size22
Treatment 
visit
Treatment 
interval
Dose 
concentration 
(PFU/mL)
Prioritization of lesions to be injected Injection volume based on 
lesion size
Lesion sizea Injection volume
initial – 106 (1 million) Inject largest lesion(s) first
.5 cm
.2.5–5 cm
.1.5–2.5 cm
.0.5–1.5 cm
#0.5 cm
Up to 4 mL
Up to 2 mL
Up to 1 mL
Up to 0.5 mL
Up to 0.1 mL
Prioritize injection of remaining lesions based on 
lesion size until maximum injection volume is reached
Second 3 weeks 
after initial 
treatment
108 (100 million) Inject any new lesions (lesions may have developed 
since initial treatment)
Prioritize injection of remaining lesions based on 
lesion size until maximum injection volume is reached
All 
subsequent 
visitsb
2 weeks after 
previous 
treatment
108 (100 million) Inject any new lesions (lesions may have developed 
since initial treatment)
Prioritize injection of remaining lesions based on 
lesion size until maximum injection volume is reached
Notes: aLongest diameter. bincluding reinitiation of treatment.
Abbreviation: PFU, plaque­forming units.
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stored in its original vial or in a syringe. According to the 
current guidance, the maximum storage times for this agent 
in the refrigerator (2°C–8°C) or at room temperature (up 
to 25°C) are shown in Table 4.22,34 Any thawed talimogene 
laherparepvec that has not been used after these storage times 
must be disposed of in accordance with local institutional 
guidelines/procedures for disposal of biohazard materials 
(described in the “Disposal and accidental spillage and 
exposure” section).
To permit seroconversion of HSV-1-negative patients 
(occurs after approximately 3–4 weeks36), the recommended 
initial talimogene laherparepvec dose is up to 4 mL at a con-
centration of 106 PFU/mL (as dose-limiting local reactions 
occurred in seronegative patients at 107 PFU/mL) (Table 3).22 
Successive doses should be up to 4 mL at a concentration of 
108 PFU/mL. The second talimogene laherparepvec dose is 
given 3 weeks after the initial dose and subsequently admin-
istered every 2 weeks. Talimogene laherparepvec should be 
administered by intralesional injection into cutaneous, sub-
cutaneous, and/or nodal lesions that are visible, palpable, or 
detectable by ultrasound. Talimogene laherparepvec should 
only be administered by direct intralesional injection – it 
cannot be administered intravenously. It is also not approved 
for direct injection into visceral metastases. When necrosis is 
present in larger lesions, injection of the lesion border should 
be considered to facilitate injection of viable tumor cells. As 
the total injection volume should not exceed 4 mL, it may 
not be possible to inject all lesions at each treatment visit or 
over the course of the treatment.
Disposable protective specialist infection control gowns, 
safety glasses or face shields, and gloves should be worn 
while preparing and/or administering talimogene laher-
parepvec. Staff handling talimogene laherparepvec should 
cover any exposed wounds before the injection and avoid 
any contact with skin, mucosa, and eyes. The cap of the 
vial should be swabbed with alcohol before inserting the 
needle that is used to draw up the desired volume into a 
sterile syringe. The aim is to reach the entire lesion area 
using the smallest-gauge needle and with as few punctures 
of the skin as possible; where injection volumes are small, 
small-unit syringes (eg, 0.5 mL) may provide improved 
injection control. In Switzerland, 25-gauge needles are 
routinely used for injecting subcutaneous melanomas, 
whereas 25-mm-long, 24-gauge needles are used to inject 
lymph node lesions. It may be beneficial to use a screw-on 
rather than push-on needle to reduce the likelihood of 
detachment during the injection process (as a relatively 
high pressure may be generated, eg, in fibrotic/scirrhous 
lesions) (author personal experience). A note should be 
taken of the total volume withdrawn. The injection site 
may be pretreated with a topical anesthetic agent or an 
injectable local anesthetic; however, a local anesthetic 
must not be injected directly into the lesion. The anesthetic 
should also not be mixed together with talimogene laher-
parepvec in the same syringe. The area should be swabbed 
with alcohol and allowed to dry ahead of administering 
talimogene laherparepvec.
Using a single insertion point, talimogene laherparepvec 
should be injected and redirected along multiple tracks 
as far as the radial reach of the needle allows to achieve 
complete dispersion within the lesion (Figure 3). Multiple 
insertion points can be used if a lesion is larger than the 
radial reach of the needle. The needle should always be 
withdrawn from the skin slowly (perhaps even allowing a 
period of 15–30 seconds from the end of injection before 
initiating needle withdrawal), to minimize the risk of leak-
age of injectate back through the puncture site. Any time the 
needle is completely withdrawn from a lesion or a different 
lesion is injected, a new needle should be used. An anima-
tion and video of the injection process are also available at 
https://www.imlygic.eu/dosing-administration and http://
www.imlygic.com/#resources, respectively. Following 
administration, the injection site should be covered with 
sterile gauze, and pressure applied for at least 30 seconds 
before swabbing the area with alcohol. Gloves should be 
changed prior to covering the injected lesion with an absor-
bent pad and a dry occlusive dressing. Alternatively, the 
HCP can initially wear two pairs of gloves and remove one 
pair postinjection, ahead of applying the dressings. In many 
institutions, dressings are applied by nurses who at the same 
time instruct the patient as to how this should be done. 
Table 4 Maximum storage times for talimogene laherparepvec22
Storage 
temperature
Maximum storage time for thawed 
talimogene laherparepvec in syringe
106 (1 million) 
PFU/mL
108 (100 million) 
PFU/mL
2°C to 8°C 8 hours 16 hours
Up to 25°C 2.5 hours 4 hours
Storage 
temperature
Maximum cumulative storage timea for 
thawed talimogene laherparepvec
106 (1 million) 
PFU/mL
108 (100 million) 
PFU/mL
2°C to 8°C 31 hours 6 weeks (42 days)
Up to 25°C 17 hours 85 hours
Note: ain vial plus storage time in syringe.
Abbreviation: PFU, plaque­forming units.
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The patient should be advised to keep the dressings in place 
for at least 8 days following each injection, or longer if the 
injection site is oozing or weeping. Dressings should be 
replaced if they fall off (and reapplied as advised by their 
HCP), and hands should be washed afterwards.
In the case of ultrasound-guided injection, some centers 
use a disposable bag (an ultrasound probe cover) over the 
scanner to avoid contamination. This can then be disposed 
of along with any other material that may have come into 
contact with talimogene laherparepvec.
Talimogene laherparepvec is contraindicated in patients 
who are severely immunocompromised (eg, those with severe 
congenital or acquired immune deficiency). HCPs who are 
immunocompromised or pregnant should not prepare or 
administer talimogene laherparepvec and should not come 
into direct contact with the injection sites, dressings, or body 
fluids of treated patients.
Disposal and accidental spillage and exposure
Local institutional guidelines should be followed for waste 
disposal and accidental spills.22 All materials that have 
come into contact with talimogene laherparepvec (eg, vials, 
syringes, needles, gauze, etc) should also be disposed of in 
accordance with local institutional procedures. In the clinic, 
potentially contaminated dressings or cleaning materials 
should be placed in a sealed plastic bag and disposed of 
in accordance with local guidelines. For example, based 
on the author’s experience in the UK, all potentially con-
taminated material is disposed of in a gene therapy waste 
disposal box, and the contents are subsequently autoclaved. 
Similarly, in Switzerland, all materials that have come 
into contact with talimogene laherparepvec are disposed 
of in special biohazard/biosafety bags, which then go 
directly for autoclaving. All talimogene laherparepvec 
spillages should be cleaned up using absorbent materials 
along with a virucidal agent. Talimogene laherparepvec is 
susceptible to common disinfectants such as 2.5% bleach, 
70% isopropyl alcohol, or 0.8% vesphene,37 as well as 
commercial agents like Virkon™ (LANXESS, Cologne, 
Germany) and Trigene® (MediChem International Ltd, 
Sevenoaks, UK) (author personal experience). In the 
event of accidental exposure (eg, splashback to the eyes 
or mucous membranes), the area should be flushed with 
clean water for at least 15 minutes. If accidental needle 
stick injury or exposure of broken skin occurs, the area 
should be cleaned thoroughly with soap and water and/or 
disinfectant. If a person who is accidentally exposed to tali-
mogene laherparepvec develops suspected herpetic lesions, 
it is at the discretion of the treating physician whether to 
take samples or swabs and send these to a central testing 
center to undergo polymerase chain reaction (PCR) testing 
for talimogene laherparepvec DNA. This test is funded 
by the manufacturer and aims to determine whether the 
infection is due to wild-type herpes virus or talimogene 
laherparepvec. As of April 28, 2015, there had been four 
reports of accidental exposure (three needlestick injuries 
and one splashback to the eye) in three HCPs during a total 
of 4100 treatment visits (https://www.fda.gov/downloads/
AdvisoryCommittees/CommitteesMeetingMaterials/
BloodVaccinesandOtherBiologics/CellularTissueandGe
neTherapiesAdvisoryCommittee/UCM444715.pdf). The 
HCP experiencing splashback to the eye was asymptom-
atic and required no further treatment. One of the HCPs 
experiencing a needlestick injury was also asymptomatic 
but was treated with an antiviral agent, and the second HCP 
experienced two needlestick injuries; they developed a her-
petic whitlow following the first incident that resolved after 
acyclovir administration but had no symptoms after the 
second incident. The remaining needlestick injury occurred 
in the preclinical setting. HCPs are asked to report any 
A B C
Cutaneous
Subcutaneous
Nodal
Cutaneous
Subcutaneous
Nodal
Cutaneous
Subcutaneous
Nodal
Figure 3 Diagram showing intralesional injection of talimogene laherparepvec into (A) cutaneous, (B) subcutaneous, and (C) nodal lesions. Copyright of Amgen inc., 
reproduced with permission.22
Notes: Using a single injection point, talimogene laherparepvec should be injected and redirected along multiple tracks as far as the radial reach of the needle allows to 
achieve complete and even dispersion within the lesion. The needle should be withdrawn slowly to avoid leakage.
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suspected adverse reactions (including suspected herpetic 
events in HCPs, patients, and their close contacts), as per 
their usual procedures.
Precautions and considerations during patient 
follow­up
Encouragingly, data from both completed and ongoing 
Phase I/II talimogene laherparepvec studies suggest that the 
incidence of viral shedding is rare, with a low frequency 
of virus detectable in swabs from the injection site27,38,39 
and no positive swab results obtained from the exterior of 
dressings.27 Viral shedding evaluations also suggest that viral 
excretion to urine or feces is very low (http://www.ema.
europa.eu/docs/en_GB/document_library/EPAR_-_Public_
assessment_report/human/002771/WC500201082.pdf), and 
no specific measures or precautions are required with regard 
to the use of bathroom facilities. An ongoing Phase II trial 
(NCT02014441) in patients with stage IIIB–IVM1c mela-
noma is further investigating the biodistribution and potential 
for shedding with this agent. Recently reported interim results 
from 30 patients treated in this study also indicate a low 
potential for transmission of talimogene laherparepvec from 
treated individuals to HCPs and close contacts, when this 
agent is administered as indicated.39 Viral DNA was occa-
sionally detected on the exterior of the occlusive dressing; in 
contrast, no live virus was found, indicating that the occlusive 
dressing forms an effective barrier for potential transmis-
sion from lesions injected with talimogene laherparepvec. 
Nevertheless, after administration, patients should be advised 
to avoid touching or scratching the injection site as this could 
lead to inadvertent transfer of talimogene laherparepvec to 
other parts of their body or to their close contacts.22 It is also 
recommended that while on treatment and within 30 days 
after treatment with talimogene laherparepvec, patients 
should use a condom during sexual contact to prevent pos-
sible virus transmission, although sexual transmission during 
or after treatment has not been documented to date. There 
are no restrictions on the patient in terms of advice to avoid 
public spaces, such as restaurants or bathrooms. Key points 
to discuss with patients regarding how to avoid spreading 
talimogene laherparepvec are summarized in Figure 4. As a 
HSV-1-based agent, talimogene laherparepvec is susceptible 
to soap and common disinfectants, and so, regular handwash-
ing is recommended, particularly after any contact with the 
injection site or contaminated dressings.
As with other immunotherapies, patients on talimogene 
laherparepvec may experience an increase in the size of 
existing tumor lesions (so-called pseudo-progression) or the 
appearance of new lesions (ie, progression) prior to achieving 
a response.30 Therefore, immune-related response criteria 
(eg, irRC)40 or immune-related Response Evaluation Crite-
ria In Solid Tumors (RECIST)41 could be used to monitor 
• Avoid direct contact between injection sites/body fluids and close contacts for the duration
 of talimogene laherparepvec treatment and until 30 days after the last dose
  � To minimize risk of exposure of blood and body fluids to close contacts, the
   following activities should be avoided:
    � Sexual intercourse without a latex condom
    � Kissing if either party has an open mouth sore
    � Common usage of cutlery, crockery, and drinking vessels
    � Common usage of injection needles, razor blades, and tooth brushes
•  Avoid touching or scratching the injection sites
• Keep injection sites covered with airtight and watertight dressings for at least 8 days
 following each injection
  � If the injection site is weeping or oozing, keep the dressing on until this stops.
   Apply dressing as instructed by your health care professional. If the dressing comes
   loose or falls off, replace it straight away with a clean dressing
• Place all used dressings and cleaning materials in a sealed plastic bag, and throw them
 away in household waste, to keep household contacts from directly touching them
  � Wash hands with soap and water after any contact with the injection site or
   contaminated dressings
• During talimogene laherparepvec treatment, there are no restrictions/special precautions
 regarding visiting public places, eg, restaurants, bathrooms, etc
Figure 4 Key points for avoiding spreading talimogene laherparepvec – advice for patients.
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
62
.2
18
.7
9 
on
 0
6-
Se
p-
20
17
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2017:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3875
Talimogene laherparepvec handling and administration
treatment response, as these take into account the patterns of 
response observed with immunotherapies, and thereby pro-
vide a better assessment of their activity than other commonly 
used criteria such as WHO criteria or RECIST (Table 5).40,42,43 
For instance, with irRC,40 the occurrence of new lesions is 
not classified as progression so long as these comprise less 
than a 25% increase in tumor burden compared with nadir, 
and are confirmed at two consecutive observations at least 
4 weeks apart. Talimogene laherparepvec treatment should be 
continued for $6 months, unless no injectable tumor lesions 
remain or the treating physician thinks that the patient is not 
benefitting or that another treatment is required. Treatment 
with talimogene laherparepvec may also be reinitiated if new 
lesions appear following a CR. 
In the Phase III OPTiM trial, talimogene laherparepvec 
was well tolerated. Nevertheless, side effects can occur, with 
the most commonly reported (affecting $25% of patients) 
being fatigue (50%), chills (49%), pyrexia (43%), nausea 
(36%), influenza-like illness (31%), and injection-site pain 
(28%). These adverse events (AEs) may be encountered 
more frequently during early treatment cycles. For example, 
influenza-like symptoms were more frequent during the 
period of the first six talimogene laherparepvec treatments, 
particularly in those who were HSV-1 seronegative at 
baseline.19 Such symptoms were mostly mild to moderate 
and generally resolved within 72 hours. If necessary, patients 
can receive antipyretic medications, such as paracetamol/
acetaminophen, and nonsteroidal anti-inflammatory drugs 
such as naproxen, diclofenac, or ibuprofen. Overall, 98% of 
AEs reported during talimogene laherparepvec treatment were 
mild or moderate in severity. The most common grade 3 or 
higher AE was cellulitis (2%),19 and therefore, careful wound 
care and infection precautions are recommended, particularly 
if tumor necrosis results in open wounds. Immune-related AEs 
such as vasculitis, pneumonitis, and vitiligo have also been 
noted during talimogene laherparepvec treatment, all events 
being nonserious and occurring in #7% of patients.19,29
Herpetic infection has been reported in some patients,22,44 
likely due to reactivation of latent wild-type HSV-1. There is 
also a potential for reactivation of talimogene laherparepvec, 
although the deletion of the neurovirulence factor, ICP34.5, 
reduces the likelihood of this event to occur. If signs or symp-
toms of herpes infection are observed, the affected individual 
should contact a HCP who may decide to evaluate the pres-
ence of DNA from talimogene laherparepvec via central PCR 
testing. If treatment is needed, talimogene laherparepvec is 
Table 5 Evaluation of response by immune­related response criteria (irRC), World Health Organization (WHO) criteria, and Response 
evaluation Criteria in Solid Tumors (ReCiST)
irRC40 WHO42 RECIST43
Method Sum of products of the two longest diameters in 
perpendicular dimensions (bidimensional)
Sum of products of the two 
longest diameters in perpendicular 
dimensions (bidimensional)
Sum of longest diameters 
(unidimensional)
Number of measured lesions index lesions (maximum 5 per organ; 10 visceral 
lesions and 5 cutaneous lesions) plus new, 
measurable lesions ($5×5 mm; up to 5 new 
lesions per organ; 5 new cutaneous lesions and 
10 visceral lesions)
All lesions Target lesions (maximum 
2 per organ; 5 in total)
New, measurable lesions $5×5 mm; incorporated into tumor burden $5×5 mm; always represent PD $10 mm; always represent PD
New non­measurable lesions ,5×5 mm; do not define PD (but precludes CR) ,5×5 mm; always represent PD ,10 mm; always represent PD
Non­index lesions Contribute to defining CR Changes contribute to defining 
best overall response of CR, PR, 
SD, and PD
Changes contribute to defining 
best overall response of CR, 
PR, SD, and PD
Response
CR Disappearance of all lesions in two consecutive 
observations not less than 4 weeks apart
Disappearance of all known 
disease, confirmed at 4 weeks
Disappearance of all known 
disease, confirmed at 4 weeks
PR $50% decrease in tumor burden compared with 
baseline in two consecutive observations not 
less than 4 weeks apart
$50% decrease, confirmed at 
4 weeks
$30% decrease, confirmed at 
4 weeks
SD Neither PR nor PD criteria met Neither PR nor PD criteria met Neither PR nor PD criteria met
PD $25% increase in tumor burden compared 
with nadir (at any single time point) in two 
consecutive observations at least 4 weeks apart
$25% increase, no CR, PR, or 
SD documented before increased 
disease, new lesion(s), $25% 
increase in 1 lesion
$20% increase, no CR, PR, 
or SD documented before 
increased disease, new lesion(s)
Abbreviations: CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.
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sensitive to commonly used antiviral/antiherpetic agents like 
acyclovir (an antimetabolite of thymidine kinase), as the gene 
for thymidine kinase in this GMO is unchanged.
As part of the controlled distribution program requested by 
the EMA, which is also followed by Swissmedic, regulatory-
approved information brochures designed specifically for 
physicians and patients/their close contacts are provided to 
inform them about the potential risks associated with talimo-
gene laherparepvec treatment, as well as handling instructions 
and protective measures. Further information on the con-
trolled distribution program (including training) is provided 
in the “Discussion” section.
Patient case studies
Examples of the use of standard and ultrasound-guided 
administration of talimogene laherparepvec in two patients 
undergoing treatment are summarized in Figure 5. As 
patient 1 had cutaneous lesions that were visible on clinical 
 
Case presentation and history
• 82-year-old female diagnosed with melanoma in lower right leg in November 2014
   • Breslow thickness: 1.85 mm
   • Clark level IV
   • Ulceration
   • BRAF wild-type
• Comorbidities of hypertension, venous insufficiency of lower extremities, dyslipidemia, and nephropathy
• Surgery of primary tumor
   • Sentinel node biopsy not performed (patient decision)
• Metastasis in March 2015
   • Cutaneous lesions in lower right leg: stage IIIC
• Entry into talimogene laherparepvec trial (NCT02366195)
Standard talimogene laherparepvec administration
• Standard administration was used as cutaneous lesions were visible on clinical examination
• Administration at week 12 (cycle 6): 4 syringes prepared containing the correct volume of drug
 for each lesion (index lesion 1: 1 mL; 2: 0.5 mL and 3: 0.5 mL; non-index lesion: 0.1 mL)
• Needle entry point outside of lesion as patient was prone to bleeding and index lesion 1 was painful and as
 remaining lesions were small and difficult to reach (permitting some fanning of the needle during injection)
• Absorbent pads used to absorb any leakage from the lesion during injection
• At baseline (week 0) total tumor surface area: 1,062 mm2
• At week 12 (cycle 6) total tumor surface area: 411 mm2
   • Index lesion 1: 20×13 mm; 2: 10×4 mm and 3: 12×8 mm; non-index lesion: 5×3 mm
Patient follow-up
• Last talimogene laherparepvec administration was week 26 (cycle 13)
 • Index lesions 1 and 2: CR
 • Index lesion 3: 4×3 mm was the only injected lesion
• At week 28, index lesion 3 biopsied
 • Infiltrate containing melanophages and lymphocytes
 • CR confirmed; patient still in CR as of June 2016 (response duration at last follow-up: 6 months)
Inject Y-VEC intralesionally using a single insertion point
Figure 5 (Continued)
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examination, standard administration was used, whereas the 
presence of subcutaneous lesions in patient 2 required the 
use of ultrasound guidance. These patients received treatment 
during a Phase II trial evaluating the correlation between 
CD8+ density and response to talimogene laherparepvec 
in unresected melanoma (NCT02366195). At the time of 
talimogene laherparepvec administration, both patients had 
stage IIIC melanoma with multiple lesions in the lower leg. 
Both patients were still in CR at last follow-up (response 
duration at last follow-up, 6 months and 10 months, for 
cases 1 and 2, respectively). Further information regarding 
these two cases, including videos of the talimogene laher-
parepvec administration process, is available in Supplemen-
tary material. 
Case presentation and history
• 44-year-old male patient diagnosed with stage IIIB melanoma in the lower right leg in April 2013
  • Breslow thickness: 3.20 mm
  • Clark level IV
  • 4–5 mitosis/mm2
  • Ulcerated (reepithelialization)
  • pT3b
  • Sentinel node positive (T3 N1a) and lymphadenectomy
  • BRAF mutant
• February–June 2014: high-dose interferon
• July 2014: high-dose interferon treatment interrupted due to cutaneous progression (stage IIIC)
  • Treatment: surgery of cutaneous metastasis, free of disease
• December 2014: appearance of 2 new lesions in subcutaneous tissue
  • Treatment: surgery, no systemic disease
• May 2015: progression with 6 new lesions in subcutaneous tissue
• Entry into talimogene laherparepvec trial (NCT02366195)
Ultrasound-guided talimogene laherparepvec administration
•  Administration was ultrasound-guided as subcutaneous lesions were present
•  At baseline (week 0) total tumor surface area: 813 mm2
•  At week 12 (cycle 6) total tumor surface area: 336 mm2
  • Index lesion 1: 4x2 mm; 2: 3x3 mm; 3: 14x13 mm; 4: 9x6 mm; 5: 0x0 mm; 6: 9x9 mm
• Administration at week 12 (cycle 6): 4 syringes prepared containing the correct volume of drug for each
 lesion (index lesion 2: 0.1 mL; 3: 0.5 mL; 4: 0.5 mL; 6: 0.5 mL [index lesion 1 {nodal} and 5 {CR}:
 no drug administered])
• At week 14 (cycle 7), index lesions 4 and 6 active, with the remaining 4 in CR
Patient follow-up
• Last talimogene laherparepvec administration was January 2016
• Index lesion 4 was the only injected lesion
• Radiological CR and talimogene laherparepvec discontinued
• Index lesion 4 was confirmed to be in CR by biopsy and was still necrotic in June 2016
• Patient still in CR as of September 2016 (response duration at last follow-up: 10 months)
Figure 5 Case studies demonstrating standard and ultrasound­guided administration of talimogene laherparepvec. The yellow oval indicates the injected lesion under 
ultrasound guidance. The patients provided written informed consent for the publication of the case details and any accompanying images.
Abbreviation: CR, complete response.
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Discussion
Because of the special requirements mentioned above, and 
as talimogene laherparepvec is classified as an ATMP, it 
will initially be available in Europe only through a special 
controlled distribution program. This will also mean that the 
product supply chain will be managed to ensure that cold 
storage requirements are met. Initially, in Europe, distribution 
will be limited to qualified centers that commit to ensuring 
that HCPs: 1) are adequately trained to minimize the risk 
of side effects (such as herpetic infections) in themselves, 
patients, and their close contacts; 2) agree to provide their 
patients with specified safety and handling information; 
3) are trained on the need for correct storage, traceability, 
handling, and patient follow-up, and 4) are aware of the 
correct process for reporting adverse drug reactions. As 
pharmacists are generally experienced in handling hazard-
ous materials (eg, chemotherapy), only minor adaptations 
to their current practices will be needed when working with 
talimogene laherparepvec.
Initially, it is likely that only centers experienced in using 
talimogene laherparepvec or oncolytic/genetically modi-
fied viruses will be able to administer this treatment. In the 
future, these larger, more experienced clinical centers could 
potentially offer training and support to smaller centers that 
would like to start using this agent. This will help to ensure 
that SOPs are shared and any potential barriers to initiating 
treatment can be overcome. However, it is possible that in 
some countries or regions, talimogene laherparepvec admin-
istration may remain limited to larger centers.
Different specialists are likely to be involved at differ-
ent stages of the handling and administration of talimogene 
laherparepvec depending on the capabilities of each center: 
for example, the treating physician (ie, a dermatologist, 
oncologist, dermato-oncologist, or surgeon) or nurse (in some 
countries) for cutaneous/subcutaneous administration of 
talimogene laherparepvec, pharmacists or nurses for storage/
preparation, and radiologists for ultrasound imaging of 
nodal lesions prior to and during talimogene laherparepvec 
administration. Furthermore, practice also differs between 
countries. For example, in the UK, melanoma treatment 
has historically been managed by radiation/medical oncolo-
gists, whereas elsewhere in Europe, it varies by country and 
site. In Germany and Austria, a dermato-oncologist is often 
responsible for melanoma treatment; dermato-oncologists 
are also involved in treatment in melanoma referral centers 
in France, Italy, Spain, and Switzerland, and here, they are 
also sometimes primarily responsible for treatment. In the 
US, surgeons and oncologists generally provide treatment. 
As many specialists are likely to be involved at different 
stages of the talimogene laherparepvec handling and admin-
istration process, there is a need for good interdisciplinary 
collaboration when using this agent.
In Europe, within the framework of clinical research, 
handling procedures for infective microorganisms, includ-
ing GMOs, are defined under four different biosafety 
levels (BSL-1–4), depending on the level of perceived risk 
(http://www.who.int/ihr/publications/WHO_CDS_CSR_
LYO_2004_11/en/).45 Microorganisms believed to be at no 
or low risk of causing disease in humans or animals and 
so have no special requirements for handling are classified 
as BSL-1, while those that can cause disease but that are 
unlikely to be a serious hazard to laboratory workers are 
classified as BSL-2. With the use of protective clothing, 
BSL-2 organisms can still be handled on an open bench, but 
a biological safety cabinet may be needed where there is the 
potential for aerosol formation. BSL-3 pathogens usually 
cause serious human or animal disease but are not readily 
spread between individuals, and effective prevention and 
treatment strategies are usually available. Such organisms 
should always be handled in a biological safety cabinet. The 
highest designation (BSL-4) is rarely used, being reserved 
for pathogens that usually cause serious disease in humans 
or animals, are readily transmitted, and for which effective 
treatment or preventative measures are generally not avail-
able. BSL-4 organisms can only be handled in specialized 
dangerous pathogen units. Before talimogene laherparepvec 
received its marketing authorization, each country performed 
its own assessment to determine the BSL level that should 
be used during clinical trials, and so, there are currently 
some differences between European countries in biosafety/
handling requirements. For example, a BSL-1 designation 
was used during the Phase III OPTiM clinical trial in the UK, 
whereas BSL-2 was used in Germany, although BSL-1 is now 
being used here too following a recent reclassification by the 
German authorities (http://apps2.bvl.bund.de/organismen/
organisms.jsf;jsessionid=ncbJnjAV3BpaqxsyMIZLVWN9.
undefined). Requirements also differ in the US, and there is 
no reference to a BSL categorization in the US prescribing 
information for talimogene laherparepvec.21,46 Nonetheless, 
the safety data sheet for talimogene laherparepvec states that 
BSL-1 containment and work practices are appropriate for 
most research and development activities handling volumes 
less than 10 L and for medical facilities administering the 
product in single-dose vials.37 Where volumes greater than 
10 L are being used (eg, in a manufacturing setting), use 
of large-scale BSL-2 containment and work practices is 
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Talimogene laherparepvec handling and administration
recommended. As part of the marketing authorization pro-
cess, a full environmental risk assessment was submitted to 
the EMA. The Committee for Medicinal Products for Human 
Use concluded that the overall risk posed by talimogene 
laherparepvec was low. Now that marketing authorization 
has been granted, use of this agent in clinical practice should 
be in line with the guidelines included in the SmPCs (which 
do not refer to any particular BSL designation).22 Nonethe-
less, each country has its own national regulatory authority 
with respect to biosafety requirements (eg, http://www.ema.
europa.eu/ema/index.jsp?curl=pages/medicines/general/
general_content_000155.jsp). For instance, Swissmedic, the 
regulatory authority in Switzerland, provided the framework 
for talimogene laherparepvec handling and administration, 
personal protective equipment, and spills/waste disposal dur-
ing clinical trials in Switzerland, but then each site developed 
its own local process to meet these requirements. Adaptations 
to a national framework may also be needed at individual 
institutions depending on local factors such as infrastructure, 
staff resources, and internal/local regulatory/safety SOPs.
In summary, talimogene laherparepvec is a novel onco-
lytic immunotherapy that has demonstrated proven efficacy 
and good tolerability in patients with stage IIIB–IVM1a 
melanoma. In line with this, talimogene laherparepvec has 
been approved in Europe for the treatment of adults with 
unresectable melanoma that is regionally or distantly meta-
static (stage IIIB, IIIC, and IVM1a) with no bone, brain, lung, 
or other visceral disease.22 Although its storage, handling, 
administration, and disposal require special attention, use in 
clinical trials and the commercial setting to date has shown 
that these can be effectively managed. Effective manage-
ment may involve tailoring of processes to site-specific local 
factors such as infrastructure, staff resources, and institutional 
guidelines, as well as the development and implementation 
of training and straightforward SOPs.
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